Prot# SHH4429g: A Randomized, Placebo-Controlled Phase II Study of GDC-0449 (Systemic Hedgehog Antagonist) with Concurrent Chemotherapy and Bevacizumab as First-Line Therapy for Metastatic Colorectal Cancer